Found: 11
Select item for more details and to access through your institution.
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
- Published in:
- Oncologist, 2023, v. 28, n. 11, p. 928, doi. 10.1093/oncolo/oyad149
- By:
- Publication type:
- Article
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
- Published in:
- European Journal of Medical Research, 2022, v. 27, n. 1, p. 1, doi. 10.1186/s40001-022-00732-w
- By:
- Publication type:
- Article
Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases: A multicenter, retrospective cohort study.
- Published in:
- Journal of Surgical Oncology, 2021, v. 123, n. 1, p. 252, doi. 10.1002/jso.26270
- By:
- Publication type:
- Article
Treating Biliary Tract Cancers: New Targets and Therapies.
- Published in:
- Drugs, 2022, v. 82, n. 17, p. 1629, doi. 10.1007/s40265-022-01808-x
- By:
- Publication type:
- Article
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 3, p. 476, doi. 10.1038/s41416-023-02534-1
- By:
- Publication type:
- Article
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.
- Published in:
- Current Oncology, 2023, v. 30, n. 7, p. 6432, doi. 10.3390/curroncol30070473
- By:
- Publication type:
- Article
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00345
- By:
- Publication type:
- Article
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
- Published in:
- Journal of Investigative Medicine High Impact Case Reports, 2022, p. 1, doi. 10.1177/23247096221129470
- By:
- Publication type:
- Article
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
- Published in:
- Journal of Investigative Medicine High Impact Case Reports, 2022, v. 10, p. 1, doi. 10.1177/23247096221129470
- By:
- Publication type:
- Article
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 7, p. 870, doi. 10.1093/jnci/djad046
- By:
- Publication type:
- Article